In a cleanroom in Kyoto, a machine the size of a paperback is quietly growing a human's stem cells. No giant vat. No army of technicians. Just a sealed cassette doing, automatically, what used to take a doctorate and a fortune. This is I Peace, and it has decided that regenerative medicine has a manufacturing problem worth solving.
A factory wearing a lab coat
I Peace, Inc. is a biotech with two addresses and one obsession. From Palo Alto and a Kyoto plant it calls Peace Engine, the company makes induced pluripotent stem cells - iPSCs, the blank-slate cells that can become almost any tissue in the body - and it makes them at clinical grade, by the hundreds of lines, for anyone with a therapy to build or a body to maintain.
Most of the field treats iPS cells as precious, artisanal, made one heroic batch at a time. I Peace treats them as product. It runs as a CDMO - a contract manufacturer - supplying GMP-grade cells to pharmaceutical companies, biotechs and universities, while also banking cells for individuals through a service it calls My Peace. The pitch is unglamorous and, for that reason, convincing: someone has to actually produce the cells everyone else turns into cures.
"Protect health and support a happier life for each person through iPSC technology."
The science arrived. The supply chain didn't.
In 2006, Shinya Yamanaka showed the world you could take an ordinary adult cell and reprogram it back to an embryonic-like state. It won a Nobel Prize and rewrote biology. It also created a bottleneck that nobody talks about at galas: making those cells, reliably, to a standard a regulator will sign off on, is brutally hard and absurdly expensive.
For years, producing a personal line of clinical-grade iPS cells could cost several million dollars and consume a facility's entire annual capacity for a single patient. The therapies were real. The math was not. A treatment that only the world's wealthiest few can afford is, in the politest possible terms, a science project with a gift shop.
"The bottleneck in cell therapy was never the science. It was the manufacturing."
Koji Tanabe knew where the bodies were buried
He should. Koji Tanabe spent eight years inside Yamanaka's lab at Kyoto University, starting in 2006, in the earliest days of iPSC research. He is the second author on the paper that first reported the successful generation of human iPS cells - which is to say he was in the room when the field began. He then crossed the Pacific to Stanford, joining Marius Wernig's lab, where direct reprogramming of skin cells into neural cells was pioneered.
Tanabe's bet, when he founded I Peace in 2015, was not that he could make a better cell. It was that he could make the same cell the way a factory makes anything: automated, enclosed, repeatable, cheap. He shrank the process into a closed, palm-sized cassette driven by robotics and fluidics, so dozens of separate cell lines could be produced in parallel without a human hand introducing contamination. The unglamorous insight - that the real frontier was the assembly line, not the microscope - is exactly the kind that tends to be right.
"We aim to bring the power of iPS cell technology to everyone - so people can take charge of their own longevity."
Cells, by the line
What I Peace sells is range. At one end sits the GMP manufacturing service: clinical-grade iPSCs made to cGMP standards that satisfy regulators in both the United States and Japan - the company holds a manufacturing license from Japan's Ministry of Health, Labour and Welfare (granted March 11, 2020) and is registered as a drug establishment with the US FDA. At the other end sits My Peace, where an individual can have their own youthful cells produced and frozen for whatever medicine the next few decades invents.
In between are research-grade cells for drug discovery, differentiated cell products, and, since April 2025, longevity and rejuvenation therapies offered directly in the US. The through-line is the cassette. Because the platform produces hundreds of lines a year instead of one, the price of a personal line fell from millions of dollars to thousands - a roughly thousand-fold change that turns a luxury into something closer to a service.
A short history of making the impossible boring
The price of being you, in stem cells
Partners who needed cells, not promises
A manufacturer is only as credible as the companies that depend on it. I Peace supplies GMP iPSCs to Avery Therapeutics for MyCardia, an iPSC-derived therapeutic aimed at heart failure, and works with Vita Therapeutics on a universal iPSC program for FSHD, a form of muscular dystrophy. The California Institute for Regenerative Medicine - CIRM, the state's $5.5 billion stem cell agency - brought I Peace into its Industry Resource Partner Program in 2022 to feed GMP cells into funded research.
There are research collaborations with Stanford and UCSF, a 2025 strategic alliance with FUNROOTS and Reju, and ISO/IEC 17025 accreditation to keep the quality auditors content. The number that arguably matters most is the plainest one: 100 GMP-grade iPS cell lines made, cumulatively, by January 2025. Lines on a shelf are harder to argue with than slides in a deck.
"Lines on a shelf are harder to argue with than slides in a deck."
Stem cells for everyone, or it doesn't count
The company's stated goal - health and a happier life for each person, through iPSC technology - sounds like the kind of thing every biotech embroiders on a banner. The difference is that I Peace's whole product strategy is downstream of it. You do not build a thousand-fold cost reduction and a palm-sized factory unless you actually intend for ordinary people to be the customers. Accessibility is not the marketing here; it is the engineering spec.
That is also the quiet wager about longevity. If your own youthful cells can be banked cheaply today and deployed against whatever medicine matures tomorrow, the value of I Peace's service compounds with time. It is a bet that the future of regenerative medicine will be limited less by what we can grow than by what we can afford.
Back to the cassette
Return to that paperback-sized machine in Kyoto, still working. A decade ago, the cells inside it would have been a multimillion-dollar event reserved for a single patient and a long waiting list. Today the same machine runs alongside dozens of its siblings, each growing a different person's biology, each line destined for a therapy, a study, or a bank vault marked with someone's name.
The science that made iPS cells possible already won its Nobel. I Peace is chasing the less celebrated prize: making the cells routine, affordable, and boring enough to actually use. If they pull it off, the most radical thing about regenerative medicine will be how unremarkable it feels to receive it.